Enfuvirtide (T-20, Fuzeon)

The Latest

Promo Image

Continuous Infusion of T-20 in Multidrug Resistant Patient With Intolerance of Subcutaneous Injections

A poster from NW Neijzen and colleagues from UMC Utrecht reported on using continuous infusion of enfuvirtide (T-20) using a tunnelled central venous catheter in a 70 year old patient with multidrug HIV resistance and intolerance to subcutaneous inje...

Promo Image

Update to Fuzeon (Enfuvirtide) Label Regarding Incidence of Bacterial Pneumonia

Updates to the Warnings and Precautions, Pneumonia subsection of the Fuzeon (enfuvirtide) package insert were approved on April 28, 2011 in response to results of a study conducted under a Postmarketing Commitment. Drug sponsor, Roche, submitted the ...

Promo Image

Important Changes to Fuzeon Product Labeling

Important additions have been made to the Fuzeon (enfuvirtide) for injection product label to include a description of nerve bundle pain, hematoma, and cautionary wording regarding Biojector use in patients with coagulopathy. The changes add language...

Promo Image

A Guide to Fuzeon: The First Fusion Inhibitor

To view other booklets from The Body, click here.C O N T E N T SFuzeon: In a Class by ItselfAnother Class of HIV Meds? Why?How Does Fuzeon Work?Cold Fusion: How HIV Gets Into Our CellsWho Should Take Fuzeon?Life Wit...

Promo Image

Fuzeon (Enfuvirtide, T-20) Accelerated to Traditional Approval/Label Revisions

FDA approved, on October 15, 2004, a supplemental new drug application for Fuzeon (enfuvirtide, also known as T-20) injection, in combination with other antiretroviral agents, for the treatment of HIV-1 infection in treatment experienced patients wit...

Promo Image

Fuzeon Accelerated Simultaneous Access Program (Fuzeon ASAP)

Dear Doctor,

Roche and Trimeris are pleased to announce the Fuzeon® (enfuvirtide) Accelerated Simultaneous Access Program (Fuzeon ASAP). This program is designed to provide immediate access to up to a 60-day supply of Fuzeon for patients who are pre...

Promo Image

Enfuvirtide Benefits Persist for at Least 2 Years

The TORO (T-20 versus Optimized Regimen Only) studies have been the primary sources of data on the new drug enfuvirtide (T-20, Fuzeon). Enfuvirtide -- the first and still the only available agent in the new, fourth class of antivirals called entry in...

Promo Image

Global Guidelines Published on Enfuvirtide Use

On Monday in Paris, a panel of experts presented international guidelines for treating HIV patients with Fuzeon, the first of a new class of drugs that can be a lifeline for people who develop resistance to other antiretrovirals. "By providing clear ...

Promo Image

Fuzeon Fizzles: Bungled T-20 Launch Claims Its First Casualties, as Losses Spread

The Year of Fuzeon: Trimeris Daily Share Price -- Launch to LabilitySource: Wall Street Journal

Curse of the "Early Terminator"

This month marks the one-year anniversary of the FDA licensure for T-20 (Fuzeon). The much anticipated and storied thera...

Promo Image
Lipodystrophy/Body Fat

No Lipodystrophy Yet Seen With Regimens Including Enfuvirtide

There has been a lot of concern regarding the contribution of many antivirals to changes in body shape -- specifically the changes in body fat called lipodystrophy. While enfuvirtide (T-20, Fuzeon) is an antiviral, it works by a completely different ...